Brokerages expect ContraFect Corp (NASDAQ:CFRX) to announce earnings of ($0.09) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for ContraFect’s earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.10). ContraFect reported earnings per share of ($0.10) in the same quarter last year, which would suggest a positive year over year growth rate of 10%. The company is scheduled to issue its next quarterly earnings results on Thursday, November 14th.
According to Zacks, analysts expect that ContraFect will report full year earnings of ($0.11) per share for the current fiscal year, with EPS estimates ranging from ($0.17) to ($0.03). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.39) per share, with EPS estimates ranging from ($0.53) to ($0.25). Zacks’ EPS averages are a mean average based on a survey of research firms that cover ContraFect.
Several equities research analysts recently commented on CFRX shares. Maxim Group started coverage on shares of ContraFect in a research report on Tuesday, June 11th. They issued a “buy” rating on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $1.50 price objective on shares of ContraFect in a research report on Wednesday, May 15th. Finally, ValuEngine raised shares of ContraFect from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
CFRX remained flat at $$0.40 during trading on Wednesday. 48,900 shares of the company traded hands, compared to its average volume of 926,951. The stock has a market capitalization of $32.16 million, a PE ratio of -1.08 and a beta of 0.07. ContraFect has a 1-year low of $0.35 and a 1-year high of $2.63. The stock’s 50 day moving average is $0.47. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.20.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
See Also: Why do corrections happen?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.